ANTENGENE-B

6996
2.5954.24% ( -0.115 )
Delay Closed: Nov 16, 16:08:11

Overview

ANTENGENE-B (6996)

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The comp...

Open
2.900
High
2.900
Low
2.525
Prev. Close
2.710
Volume
980.50K
Turnover
2.54M
Avg Price
2.586
Bid/Ask Ratio
-95.24%
Amplitude
13.84%
52wk High
6.280
Volume Ratio
0.57
Turnover Ratio
0.14%
52wk Low
2.525
HK Mkt Cap
1.77B
Market CapHKD
1.77B
P/ETTM
28.74
P/EDynamic
3.56
P/EStatic
--
EPSTTM
0.0903
EPSDynamic
0.729
EPSStatic
--
BVPS
1.54
P/B
1.69
HK Shares
683.32M
Dividend YieldTTM
--
DividendTTM
--
Shares
683.32M
Min lot size
500
Currency
HKD

ANTENGENE-B Analyst Rating

View more

Forecast & Rating

Aug 27, 2026
Price forecast
HK$4.8486.45%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Antengene opened at HK$2.900 and faded through the day to close HK$2.595, down 4.24% from HK$2.710 on 980,500 shares worth HK$2.54 million, a thin 0.14% turnover; the morning slipped from 2.650 to 2.560 and the afternoon probed 2.535, a spike-and-fade pattern whose main cause was scarce follow-through buying after the prior session's 52-week low of 2.525, with SITC preclinical readouts on ATG-109 and AnTenGager-D2, ATG-207 data and first dosing of ATG-201 already absorbed by an earlier 6% bounce. Fundamentals diverge from the tape: Q2 2026 revenue reached HK$296.3 million, up 916.9% yoy, net profit HK$124.9 million, up 398.6%, net margin 42.17% and EPS HK$0.1964, yet the price sits below MA20 of 2.826 and MA60 of 3.252, down 33.63% YTD and 58.68% below the 52-week high of 6.28, at 28.7x PE and 1.69x PB. Buybacks have continued, though the stock is only 2.77% above its 52-week low.

  2. Nov, 13

    Antengene (6996.HK) spiked and faded, opening at HK$2.950 for the session high before sliding to a HK$2.645 low in the afternoon session and closing at HK$2.710, down 3.90% from HK$2.820, on thin 503,500 shares and HK$1.36 million turnover. Q2 2026 revenue of HK$296.3 million (+916.94% yoy), net profit of HK$124.9 million (+398.58%) and a 42.17% net margin sit against PE 30.02x and PB 1.76x, yet the stock is down 30.69% year-to-date, 56.85% below its April 14 52-week high of HK$6.28 and only 3.44% above the November 2 low of HK$2.62, trading under both MA20 (2.85) and MA60 (3.276). Neither the 46.7% response rate for ATG-022 in Phase II gastric cancer, first patient dosing of ATG-201, the SITC 2026 AnTenGager-D2 data nor repeated buyback disclosures reversed the drift, though the buybacks and steady data flow offer some support.

  3. Nov, 10

    Antengene rose 4.6% to HK$2.82 as the company used SITC 2026 to release three updates in quick succession: ATG-109 outperforming a clinical benchmark in a preclinical prostate cancer model, the AnTenGager-D2 Cos-TCE platform selected for a rapid oral abstract, and first patient dosing in the Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) for B cell-mediated autoimmune diseases. The session traced a gap-up then fade: an open at HK$2.905, a morning peak of HK$2.86 at 10:47, a slide to HK$2.76, then afternoon consolidation between HK$2.80 and HK$2.84 on 391,500 shares. The tension sits between fundamentals and price: Q2 2026 revenue of HK$296.3 million (+916.9% yoy), net profit of HK$124.9 million (+398.6%) and EPS of HK$0.1964 (+391%) contrast with a close still below the MA20 of HK$2.876 and MA60 of HK$3.333, a 27.9% YTD decline and a 55.1% gap to the April 14 high of HK$6.28. Though these readouts remain early-stage, with turnover at just 0.06%.

  4. Nov, 6

    Antengene fell 4.4% to HK$2.82 from a HK$2.95 previous close in a spike-and-fade session, opening at HK$2.89 and printing the day's high of HK$2.935 in the first minutes before sliding to HK$2.725 by 14:48 BJ and settling near HK$2.755 into the 16:00 close, with successive buybacks (78,000 shares on Nov 3, 108,000 on Nov 2) failing to hold the bid and news of the first patient dosed in the Phase I ATTRACT study of ATG-201 (CD19 x CD3 TCE) doing little for sentiment. That sits against the fundamentals: Q2 2026 revenue of HK$296.3m, up 916.9% yoy, net profit HK$124.9m, a 42.2% net margin and EPS of HK$0.1964, while the stock is down 27.9% YTD, 55.1% below its 52-week high of HK$6.28 and still under the MA20 of HK$2.913 and MA60 of HK$3.392. Though the price remains only 7.6% above the Nov 2 52-week low of HK$2.62, on turnover of 0.05%.

  5. Nov, 5

    Antengene-B closed up 5.0% at HK$2.95, extending its rebound from the 52-week low of HK$2.62 set on November 2, as a run of near-daily buybacks and residual interest in ATG-022's 46.7% objective response rate in a Phase II gastric cancer trial lifted the stock to an intraday peak of HK$2.985 in the morning session, before it slipped to HK$2.90 at the 13:00 afternoon open and recovered into the close; turnover was 553,500 shares worth HK$1.62 million. Fundamentals diverge sharply from the tape: Q2 2026 revenue reached HK$296.3 million, up 916.94% year on year, with net profit of HK$124.9 million, a 42.17% net margin and EPS of HK$0.1964, yet the shares remain down 24.55% year to date, 53.03% below the April 14 high of HK$6.28 and under the MA60 of HK$3.421, holding only just above the MA20 of HK$2.937. The company repurchased 108,000 shares on November 2 and 78,000 on November 3 for HK$303,600 and HK$210,300. Though a 0.08% turnover rate and HK$2.02 billion market value suggest the bounce lacks fresh volume.

News